Literature DB >> 1617407

Indole-N-methylated beta-carbolinium ions as potential brain-bioactivated neurotoxins.

M A Collins1, E J Neafsey, K Matsubara, R J Cobuzzi, H Rollema.   

Abstract

N-Methyl-4-phenylpyridinium ion (MPP+), a highly toxic metabolite produced in the brain from a street drug contaminant, is selectively taken up by nigrostriatal dopaminergic neurons and accumulated intraneuronally in mitochondria. There it inhibits respiration, causes neuronal death and, in primates, provokes a parkinsonian condition. It has been suggested that endogenously generated or activated agents resembling MPP+ may contribute to the development of Parkinson's disease. We report here that simple beta-carbolines derived from tryptophan or related open chain indoles, when specifically methyl-substituted on both (2[beta] and 9[indole]) available nitrogens, display mitochondrial inhibitory potencies and neurotoxic effects in vitro (PC12 cultures) and in vivo (striatal microdialysis) which approach or even surpass MPP+. These results take on physiological significance with our finding that brain enzyme activity catalyzes S-adenosylmethionine-dependent methylations of the beta- and indole-nitrogens in beta-carbolines that have been detected in vivo. The unusual 9[indole]-N-methyl transfer, previously unrecognized in animals, apparently requires prior methylation of the 2[beta]-nitrogen. Sequential di-N-methylation of endogenous or xenobiotic beta-carbolines to form unique, neurotoxic 2,9-N,N'-dimethyl-beta-carbolinium ions may serve as a brain bioactivation route in chronic neurodegenerative conditions such as Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1617407     DOI: 10.1016/0006-8993(92)90576-u

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  Genetic predisposition to pancreatic cancer.

Authors:  Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Characterization of brain beta-carboline-2-N-methyltransferase, an enzyme that may play a role in idiopathic Parkinson's disease.

Authors:  D A Gearhart; E J Neafsey; M A Collins
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

Review 3.  The aetiology of idiopathic Parkinson's disease.

Authors:  D B Ramsden; R B Parsons; S L Ho; R H Waring
Journal:  Mol Pathol       Date:  2001-12

4.  Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients.

Authors:  W Kuhn; T Müller; H Grosse; H Rommelspacher
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.

Authors:  A Ostergren; A Fredriksson; E B Brittebo
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

6.  Comparison of the in vitro binding characteristics of the beta-carbolines harman and norharman in rat brain and liver and in bovine adrenal medulla.

Authors:  T May; A Greube; S Strauss; D Heineke; J Lehmann; H Rommelspacher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

7.  Inhibitory effects of lysophosphatidylcholine on the dopaminergic system.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Kennie R Shepherd; Nazarius S Lamango; Karam F A Soliman; Clivel G Charlton
Journal:  Neurochem Res       Date:  2004-07       Impact factor: 3.996

8.  Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism.

Authors:  C G Charlton; J Mack
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

9.  Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice.

Authors:  Marlaina R Stocco; Cole Tolledo; Fariba Baghai Wadji; Frank J Gonzalez; Sharon Miksys; Rachel F Tyndale
Journal:  Mol Neurobiol       Date:  2020-08-06       Impact factor: 5.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.